By November 2004, when the first issue of Nature Reviews Clinical Oncology was published, cancer immunotherapy had been successfully applied to the treatment of selected human cancers; however, dramatic progress in the following decade has moved immunotherapy from the sidelines of cancer treatment into the mainstream of modern oncology.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Lysosome blockade induces divergent metabolic programs in macrophages and tumours for cancer immunotherapy
Journal of Experimental & Clinical Cancer Research Open Access 04 August 2023
-
Why Probability isn’t Magic
Foundations of Science Open Access 01 September 2021
-
Detecting long-range interactions between migrating cells
Scientific Reports Open Access 22 July 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 422 (2010).
Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011).
Bollard, C. M. et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein–Barr virus latent membrane proteins. J. Clin. Oncol. 32, 798–808 (2012).
Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2013).
Pule, M. A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264–1270 (2008).
Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102 (2010).
Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Rosenberg, S. Entering the mainstream of cancer treatment. Nat Rev Clin Oncol 11, 630–632 (2014). https://doi.org/10.1038/nrclinonc.2014.174
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.174
This article is cited by
-
Lifileucel: First Approval
Molecular Diagnosis & Therapy (2024)
-
Lysosome blockade induces divergent metabolic programs in macrophages and tumours for cancer immunotherapy
Journal of Experimental & Clinical Cancer Research (2023)
-
Why Probability isn’t Magic
Foundations of Science (2023)
-
Diagnostic impact of 18F-FDG PET/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy
Clinical and Translational Oncology (2022)
-
Detecting long-range interactions between migrating cells
Scientific Reports (2021)